BY Scott Merville

In a pilot study of 13 newly diagnosed, BRCA-positive breast cancer patients at MD Anderson, all had their tumors shrink significantly when treated with the drug talazoparib before presurgical chemotherapy.

Tumor shrinkage after two months of treatment with the drug, measured by ultrasound, ranged from 30 to 98%, with an average reduction in tumor volume of 78% among the 13 patients.

“Acknowledging that this is a small study...

PARP inhibitors BRCA-positive breast cancer

BY Clayton Boldt, Ph.D.

Hereditary cancers are caused by genetic mutations passed down from parents to children. The National Cancer Institute estimates...